Zhitong Finance App News, Gloria Ying (06821) announced that in order to seize the booming development opportunities in the domestic and foreign innovative drug markets, explore the focus on cultivating high-quality projects through the “asset+capital+service” commercial cooperation method by investing in specialized biomedical innovation and synthetic biology industry investment funds, continue to promote the company's technical capacity building and business development needs, and achieve healthy interaction between the company's industrial resources and the resources and capital of professional investment institutions. Gloria Life Sciences, a wholly-owned subsidiary of the company, plans to invest 300 million yuan as a limited partner in the establishment of a biomedical innovation and synthetic biology industry investment fund with Haihe Fund, Eco-City State-owned Capital, Haizunchuang, and Xinyin Hengze.